May 3, 2006
Campbell Alliance, the leading management consulting firm specializing in the pharmaceutical and biotech industries, today announced that Ben Bonifant, Senior Practice Executive and head of its Business Development Practice, will be speaking at the Japan America Society of Greater Philadelphia (JASGP) Health Science Dialogue and the Licensing Executives Society (LES) and Association of University Technology Managers (AUTM) Joint Spring Meeting in Philadelphia.
The JASGP Health Science Dialogue will be held on May 9 at the Union League of Philadelphia, while the LES-AUTM Spring Meeting will be held on May 10-12 at the Loews Philadelphia Hotel. Both conferences are being held in conjunction to be better serve those business development and licensing professionals planning to attend.
The JASGP Health Science Dialogue’s theme this year is “Therapies for Cancer,” and Mr. Bonifant, along with Dr. Nobuo Hanai, President and
At the LES-AUTM Spring Meeting, Mr. Bonifant will speak on "Eleven Missteps in Valuation and How to Avoid Them," a discussion of some of the more frequently encountered errors in valuation models. The audience will then participate in an interactive discussion of how decision makers can increase the likelihood that the models they rely on reflect the “real world” of commercializing pharmaceuticals. The session will be conducted on Thursday, May 11 from to
“Every business development executive recognizes the high levels of risk and uncertainty inherent in developing and commercializing pharmaceutical products,” stated Mr. Bonifant. “Even if accurate discounts could be identified for clinical and regulatory risks, valuations would still need to reflect the uncertainties of product labeling, market adoption, and competitive entry. With so many real drivers of uncertainty, there is little room for avoidable missteps in conducting valuations,” he continued.
The JASGP started the Health Science Dialogue seven years ago with the purpose of facilitating relationships between senior executives of Japanese pharmaceutical and biotech companies and their
LES and AUTM are the two largest professional societies dedicated to licensing and intellectual asset valuation, with a total of more than 8,000 members. The LES-AUTM Spring Meeting is the first of three critical gatherings of licensing executives sponsored by LES each year. For more information, please visit http://www.usa-canada.les.org/meetings/2006spring.
About the Business Development Practice at
The firm’s team members include seasoned professionals in pharmaceutical and biotech business development. As consultants and industry professionals, they’ve identified, assessed, and executed numerous in-licensing deals, assisted out-licensors, helped clients improve internal processes for pharmaceutical business development, and helped top executives chart new strategies in corporate development.
Campbell Alliance is the leading management consulting firm specializing in the pharmaceutical and biotechnology industries. The firm's clients include most of the world's "top 20" pharmaceutical companies, as well as numerous emerging and midsize firms. Campbell Alliance is organized into practice areas, each specializing in a critical industry function, including Brand Management, Business Development, Clinical Development, Managed Markets, and Sales. From its locations in